ES2148838T3 - Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer. - Google Patents

Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.

Info

Publication number
ES2148838T3
ES2148838T3 ES97100277T ES97100277T ES2148838T3 ES 2148838 T3 ES2148838 T3 ES 2148838T3 ES 97100277 T ES97100277 T ES 97100277T ES 97100277 T ES97100277 T ES 97100277T ES 2148838 T3 ES2148838 T3 ES 2148838T3
Authority
ES
Spain
Prior art keywords
treatment
propetin
alp
camp
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97100277T
Other languages
English (en)
Inventor
Yoon S Cho-Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHO CHUNG YOON S
Original Assignee
CHO CHUNG YOON S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHO CHUNG YOON S filed Critical CHO CHUNG YOON S
Application granted granted Critical
Publication of ES2148838T3 publication Critical patent/ES2148838T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN OLIGONUCLEOTIDOS ANTISENTIDO RI AL Y COMPOSICIONES FARMACEUTICAS DE LOS MISMOS. TAMBIEN SE DESCRIBEN METODOS PARA EL TRATAMIENTO DE CIERTOS CANCERES EN ANIMALES QUE COMPRENDEN LA ADMINISTRACION A LOS ANIMALES DE UNA CANTIDAD EFECTIVA DE UN OLIGONUCLEOTIDO ANTISENTIDO RI{AL}, O UNA COMPOSICION FARMACEUTICA DEL MISMO.
ES97100277T 1990-11-02 1991-10-31 Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer. Expired - Lifetime ES2148838T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60711390A 1990-11-02 1990-11-02
US68019891A 1991-04-05 1991-04-05
US07/702,163 US5271941A (en) 1990-11-02 1991-05-20 Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Publications (1)

Publication Number Publication Date
ES2148838T3 true ES2148838T3 (es) 2000-10-16

Family

ID=27416969

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97100277T Expired - Lifetime ES2148838T3 (es) 1990-11-02 1991-10-31 Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
ES91118628T Expired - Lifetime ES2104644T3 (es) 1990-11-02 1991-10-31 Oligonucleotidos antisentido para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES91118628T Expired - Lifetime ES2104644T3 (es) 1990-11-02 1991-10-31 Oligonucleotidos antisentido para el tratamiento del cancer.

Country Status (9)

Country Link
US (3) US5271941A (es)
EP (3) EP0490077B1 (es)
KR (1) KR0171210B1 (es)
AT (2) ATE194383T1 (es)
CA (2) CA2488792A1 (es)
DE (2) DE69127175T2 (es)
DK (2) DK0490077T3 (es)
ES (2) ES2148838T3 (es)
GR (2) GR3024673T3 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6995146B2 (en) * 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
CA2158347A1 (en) 1993-03-26 1994-10-13 Renato Baserga Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US5639872A (en) * 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
ES2326118T3 (es) * 1993-09-20 2009-10-01 The Trustees Of The University Of Pennsylvania Regulacion de la expresion del gen bcl-2.
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en) * 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US20050054600A1 (en) * 1995-08-17 2005-03-10 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
JP2002501370A (ja) * 1997-03-12 2002-01-15 ハイブライドン，インク． 改良蛋白質キナーゼａ特性オリゴヌクレオチドおよびその利用方法
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
WO2000079281A1 (en) * 1999-06-18 2000-12-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6489356B2 (en) 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
EP2325337A1 (en) 2000-09-26 2011-05-25 Duke University RNA aptamers and methods for identifying the same
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
KR100408916B1 (ko) * 2000-11-23 2003-12-11 주식회사 바이오제니아 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제
US6524854B1 (en) * 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression
ATE469167T1 (de) 2002-02-06 2010-06-15 Vicor Technologies Inc Anti-infarkt-moleküle
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
US7528117B2 (en) * 2002-12-05 2009-05-05 The Research Foundation Of State University Of New York High efficacy antisense RIαPKA poly-DNP oligoribonucleotides
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
EP1744761A4 (en) * 2004-04-28 2010-01-13 Molecules For Health Inc METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
EP1765065B1 (en) 2004-05-21 2012-06-27 University of Utah Research Foundation Methods and compositions related to delivery of chemical compounds to invertebrate embryos
EP2484780A1 (en) 2004-07-23 2012-08-08 The University of North Carolina At Chapel Hill Methods and materials for determining pain sensibility and predicting and treating related disorders
US7829673B2 (en) 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
EP2189522A1 (en) 2005-10-14 2010-05-26 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
EP3034083B1 (en) 2006-09-21 2020-12-09 University of Rochester Antisense oligonucleotides for use in treating myotonic dystrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
EP2104509A4 (en) 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASCULAR PERMEABILITY
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
DK2195331T3 (da) 2007-08-28 2014-02-03 Uab Research Foundation Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
EP2853897A1 (en) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9970002B2 (en) 2012-12-12 2018-05-15 Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
WO2015077566A1 (en) 2013-11-21 2015-05-28 Huang Zhen Methods for structural determination of selenium derivatized nucleic acid complexes
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
EP3253875B1 (en) * 2015-02-04 2020-01-08 H. Hoffnabb-La Roche Ag Tau antisense oligomers and uses thereof
CN107636159B (zh) 2015-02-04 2022-06-14 百时美施贵宝公司 选择治疗性分子的方法
JP2019527229A (ja) 2016-07-28 2019-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｐｒ１５６変異体及びその使用
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
CN110446785B (zh) 2017-01-23 2024-04-26 瑞泽恩制药公司 Hsd17b13变体及其应用
SG11201911597YA (en) 2017-06-05 2020-01-30 Regeneron Pharma B4galt1 variants and uses thereof
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
WO2019051033A1 (en) 2017-09-07 2019-03-14 Regeneron Pharmaceuticals, Inc. VARIANTS OF MEMBER 1 OF SOLUT TRANSPORTER FAMILY 14 (SLC14A1) AND USES THEREOF
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
JP7434151B2 (ja) 2017-10-11 2024-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｎｐｌａ３ ｉ１４８ｍの変異を発現している患者の肝疾患の治療におけるｈｓｄ１７ｂ１３の阻害
RU2020115869A (ru) 2017-10-16 2021-11-19 Ридженерон Фармасьютикалз, Инк. Варианты корнулина (crnn) и их применение
EP3994125A1 (en) 2019-07-02 2022-05-11 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
NO864301L (no) * 1986-10-28 1988-04-29 Tore Jahnsen Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser.
JPH03505672A (ja) * 1988-07-05 1991-12-12 ベイラー カレッジ オブ メディシン 高分子合成オペロンの相補アンチセンス　オリゴヌクレオチド抗菌、バクテリヤ感染の処置方法
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Also Published As

Publication number Publication date
EP0490077B1 (en) 1997-08-06
GR3034535T3 (en) 2001-01-31
US5627158A (en) 1997-05-06
EP0785252B1 (en) 2000-07-05
US5691317A (en) 1997-11-25
CA2054325A1 (en) 1992-05-03
ATE194383T1 (de) 2000-07-15
CA2488792A1 (en) 1992-05-03
EP0972831A1 (en) 2000-01-19
DE69127175D1 (de) 1997-09-11
DK0785252T3 (da) 2000-10-02
EP0490077A1 (en) 1992-06-17
KR0171210B1 (ko) 1999-02-01
ES2104644T3 (es) 1997-10-16
DE69132299T2 (de) 2001-02-15
DK0490077T3 (da) 1998-01-26
EP0785252A1 (en) 1997-07-23
DE69127175T2 (de) 1998-03-12
CA2054325C (en) 2005-03-15
US5271941A (en) 1993-12-21
ATE156517T1 (de) 1997-08-15
GR3024673T3 (en) 1997-12-31
DE69132299D1 (de) 2000-08-10

Similar Documents

Publication Publication Date Title
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
IT1276041B1 (it) Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
ES2145836T3 (es) Copolimeros elastomericos termoplasticos injertados de silicona, y composiciones que los contienen para el cuidado del pelo y la piel.
NO304580B1 (no) Doseringsform for medikamentavgivelse med tidsvarierende m°nstre
IL101145A0 (en) Pharmaceutical compositions containing synergistic combinations of nucleoside derivatives
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
NO975858D0 (no) Anvendelse av et ekstrakt av Cimicifuga racemosa
ATE146361T1 (de) Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
AR015347A1 (es) Uso de colina para la preparacion de un medicamento o formulacion nutricional para el tratamiento del shock endotoxico y composiciones nutricionales quecomprenden colina
RS52011B (sr) Nova primena derivata taksoida
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 785252

Country of ref document: ES